A detailed history of Legal & General Group PLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 3,713 shares of ATNM stock, worth $5,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,713
Previous 3,713 -0.0%
Holding current value
$5,569
Previous $6,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.72 - $8.0 $997 - $4,640
580 Added 18.51%
3,713 $6,000
Q2 2024

Aug 14, 2024

BUY
$6.56 - $9.89 $754 - $1,137
115 Added 3.81%
3,133 $23,000
Q4 2023

Feb 15, 2024

BUY
$4.02 - $6.08 $1,740 - $2,632
433 Added 16.75%
3,018 $15,000
Q3 2023

Nov 14, 2023

SELL
$5.91 - $7.37 $3,297 - $4,112
-558 Reduced 17.75%
2,585 $15,000
Q2 2023

Aug 14, 2023

BUY
$7.15 - $9.39 $22,472 - $29,512
3,143 New
3,143 $23,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $37.8M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.